Diagnostic value of the content of antimic robial peptide C-terminal hCAP18 cathelicid in LL-37 in children with asthma
This article studied the diagnostic value content antimicrobial peptide C-terminal hCAP18 cathelitcidin LL-37 in children with asthma. To achieve this goal we examined 200 children with asthma aged from 6 to 18 years. The content of cationic antimicrobial peptide C-terminal hCAP18 cathelitcidin LL-37 in patients with asthma was significantly higher (p>0,001), than in the group of healthy children. It is established that the content cathelitcidin LL-37 is higher at nonatopic (55,73±0,54 ng/ml) and mixed (29,71±0,33 ng/ml) versions of asthma than in atopic (6,64±0,47 ng/ml), its version. Content of cathelitcidin LL-37 was significantly associated with the severity and adequate control of asthma also noted. Thus, severe persistent asthma contents cathelitcidin LL-37 higher in 39,58% and 10,87% than the intermittent and mild persistent flow respectively, while content in uncontrolled asthma was 3,76 times higher than in a controlled flow disease. The positive correlation of medium strength cathelitcidin LL-37 containing and interleukin-1 values (rxy=0,398 (p=0,02)) and 6 (rxy=0,178 (p=0,034)) in the serum of patients with asthma. Definition of methods aimed at the possibility of influencing the content cathelitcidin LL-37 in the serum of children with asthma will allow better control of the course and severity of the disease and reduce the number of complications in the future.